Coronavirus vaccine developer CanSino offers shares in China’s second-most expensive initial public offering
CanSino Biologics, the Tianjin-based pharmaceutical producer that is conducting human trials on its coronavirus vaccine,
CanSino Biologics, the Tianjin-based pharmaceutical producer that is conducting human trials on its coronavirus vaccine,